Risk factors for MDR pneumonia according to the 2017 International ERS/ESICM/ESCMID/ALAT guidelines

C. Dominedò (Rome, Italy), A. Ceccato (Barcelona, Spain), M. Niederman (New York, United States of America), A. Gabarrús (Barcelona, Spain), C. Cillóniz (Barcelona, Spain), I. Martin-Loeches (Dublin, Ireland), M. Ferrer (Barcelona, Spain), M. Antonelli (Rome, Italy), A. Torres (Barcelona, Spain)

Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Dominedò (Rome, Italy), A. Ceccato (Barcelona, Spain), M. Niederman (New York, United States of America), A. Gabarrús (Barcelona, Spain), C. Cillóniz (Barcelona, Spain), I. Martin-Loeches (Dublin, Ireland), M. Ferrer (Barcelona, Spain), M. Antonelli (Rome, Italy), A. Torres (Barcelona, Spain). Risk factors for MDR pneumonia according to the 2017 International ERS/ESICM/ESCMID/ALAT guidelines. 3304

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk factors of pneumonia in servicemen of the Russian Federation
Source: Eur Respir J 2005; 26: Suppl. 49, 144s
Year: 2005

International guidelines for nosocomial pneumonia: do they cover multidrug resistance management?
Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Year: 2019


International Recommendations for  HAP and VAP
Source: International Congress 2017 – Management of Hospital-Acquired Pneumonia (HAP)/Ventilator-associated pneumonia (VAP)
Year: 2017


Community acquired pneumonia in Greece: Clinical, microbiological data and adherence to the IDSA guidelines
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010


The implementation of IDSA/ATS and the Greek national guidelines for CAP by chest physicians in Greece
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


The adherence of Greek chest physicians to the 2007 IDSA/ATS and the Greek national guidelines for CAP
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017

Validation of the ATS/IDSA guidelines for ICU-acquired pneumonia
Source: Annual Congress 2009 - Severe sepsis and multiple organ failure
Year: 2009


European framework for tuberculosis control and elimination in countries with a low incidence: Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis
Source: Eur Respir J 2002; 19: 765-775
Year: 2002



International Guideline concordance of empiric antibiotic use in community-acquired pneumonia
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020



Adherence to GOLD 2017 Guideline and factors for pharmacological treatment adjustment in Swiss Pulmologists and General Practitioners
Source: International Congress 2019 – Innovations in primary care assessment and management
Year: 2019

Risk factors for tuberculosis relapse in Polish patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

Simplifying IDSA/ATS pneumonia guidelines
Source: Annual Congress 2013 –Viral infections: what is new?
Year: 2013


Risk factors for death among tuberculosis cases: analysis of European surveillance data
Source: Eur Respir J 2008; 31: 1256-1260
Year: 2008



World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Source: Eur Respir J , 49 (3) 1602308; DOI: 10.1183/13993003.02308-2016
Year: 2017




TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?
Source: Eur Respir J 2012; 39: 619-625
Year: 2012



European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations
Source: Eur Respir J, 52 (5) 1801617; 10.1183/13993003.01617-2018
Year: 2018



World Health Organization treatment outcome definitions for tuberculosis: 2021 update
Source: Eur Respir J, 58 (2) 2100804; 10.1183/13993003.00804-2021
Year: 2021



European Union Standards for Tuberculosis Care
Source: Eur Respir J 2012; 39: 807-819
Year: 2012